SOLARA705.85

Solara Active Pharma Sciences Limited

· Pharma & Health
₹ CrorePeersINDSWFTLABDCALSMSPHARMAHIKALPANACEABIOSAIPARENTINDOCOUNICHEMLABMcap ₹3,142 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)172.60199.49172.45172.45
Receivable Days (DSO)98.6992.85116.97116.97
Payable Days (DPO)150.20156.01148.60145.22
Cash Conversion Cycle (days)121.09136.33140.82144.20
Working Capital Turnover-2.83-5.96-38.23-39.97
Asset Turnover0.550.580.590.59
Cash Conversion (CFO/Net Income)-0.19394.11-20.64-20.64
CFO/EBITDA-1.141.030.820.82
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.